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A B S T R A C T
Papillary ﬁbroelastoma (PFE) is a rare benign tumor that most commonly involves heart valves. Cardiac
PFE involving the mitral chorda is rarer. Most papillary PFE are asymptomatic; rarely, they are diagnosed
because of cardiac symptoms or after an embolic event. In this case, a 70-year-old woman presented
with an acute cerebral ischemic infarct. Evaluation for potential embolic source revealed a mass on the
mitral chordae. The ﬁndings of cardiac magnetic resonance (CMR) tissue characterization of the mass
corroborated the diagnosis of mitral valve tumor. She underwent surgical resection of this mass and
histology, which conﬁrmed a PFE.
<Learning objective: PFE are easily detected on echocardiography but are difﬁcult to visualize with
CMR. Their small size and rapid, extensive movement render adequate CMR imaging extremely difﬁcult.
This case highlights the ability of CMR to characterize the tissue characteristics and enhancement
pattern which enables non-invasive assessment for the etiology of intra-cardiac masses and usually
distinguishes a tumor from thrombus.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Papillary ﬁbroelastomas (PFEs) are rare endocardial tumors,
predominantly affecting the cardiac valves. In particular, they
more commonly affect the aortic valve followed by the mitral valve
[1]. A non-valvular origin was observed in approximately 16% of
cases [2]. Cardiac PFE involving the mitral chorda is rarer.
Transthoracic and especially transesophageal echography (TTE;
TEE) is the most sensitive and reliable investigation to establish the
diagnosis, exclude multiple locations, and plan the optimal
surgical approach [2]. Whether a multimodality imaging approach
offers signiﬁcant added value compared with echocardiography
alone in the diagnostic evaluation of cardiac PFE is controversial.
Case report
A 70-year-old Caucasian woman presented with diffuse
weakness and expressive aphasia. Her medical history included
a previous left-sided cerebral infarct with no residual deﬁcits.* Corresponding author at: Wake Forest Baptist Medical Center, Cardiology
Section/Internal Medicine, Medical Center Boulevard, Winston-Salem, NC 27157,
USA. Tel.: +1 336 716 9075; fax: +1 336 716 9188.
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1878-5409/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsShe underwent a head computed tomography (CT) and brain
magnetic resonance imaging (MRI), which revealed an acute
ischemic infarct of the left hypothalamus, insular cortex, posterior
left frontal lobe, and left caudate nucleus. Given the concern for
potential embolism, a two-dimensional TTE was obtained, which
revealed a 13 mm  12 mm mass in relation to the subvalvular
aspect of the posterior mitral valve apparatus (Fig. 1). To examine
the characteristics of mass in detail, a TEE was performed, which
showed a 14 mm  12 mm mass on the chordae attached to the
posterior mitral leaﬂet and a 2 mm  3 mm echo density attached
to left coronary cusp of aortic valve (Fig. 1). To further characterize
this mass, imaging was obtained by cardiac magnetic resonance
(CMR). It revealed a 7 mm  8 mm round mass associated with
chordae immediately below the P2 scallop of posterior mitral
leaﬂet. This mass showed homogenous signal intensity identical to
ﬁbrous tissue on both T1 and T2 weighted sequences; fat
suppression ruled out the presence of fatty lesion components.
It did not enhance with ﬁrst-pass perfusion. T1-weighted
inversion-recovery images after intravenous administration of
gadolinium diethylene triamine pentaacetate show enhancement
of tumor caused by the ﬁbroelastic tissue of the mass (Fig. 2).
Absence of increased signal intensity on contrast-enhanced ﬁrst-
pass perfusion imaging and contrast uptake of the tumor on
delayed-enhancement imaging clearly demonstrated that this
mass is neither a malignant tumor, nor a thrombus. Cardiac reserved.
Fig. 1.
(A and B) 2D transthoracic echocardiography showing a mass attached to subvalvular apparatus of posterior mitral leaﬂet; (C) Transesophageal echocardiography
(TEE) showing a mass attached to subvalvular posterior mitral valve apparatus; (D) TEE showing the echo density attached to the left coronary cusp of aortic
valve.
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gelatinous, tumor. It was associated with the posterior papillary
muscle under the P2 scallop. This was excised along with one
tendon which was unable to be separated from the tumor (Fig. 3).
Likewise, a 2 mm mass, similar in appearance to the mitral valve
tumor was noted on the left coronary cusp and was also excised.
The histopathological examination conﬁrmed the diagnosis of a
PFE (Fig. 3). The patient made an uncomplicated recovery.
Discussion
Although the prevalence of primary cardiac tumors ranges from
0.0017% to 0.28%, the PFEs are the second most common benign
neoplasm of the cardiac valves after myxomas [2]. It can be a
source of embolization leading to strokes, particularly in those
without identiﬁable risk factors [1]. Kasarskis et al. [3] reported
that 50% of the patients with a PFE had transient ischemic attacks
or previous strokes prior to discovery of the tumor. Embolization
may occur from the fragile papillary fronds or from a platelet and
ﬁbrin aggregation forming on the tumor [4,5].
PFEs are easily detected on echocardiography, but are difﬁcult
to visualize with CMR. Their small size and rapid, extensive
movement render adequate CMR imaging extremely difﬁcult. In
the present case, the high diagnostic image quality of spin-echosequences was achieved by freezing of mitral valve motion.
The mitral valve rest period was determined from a cine sequence
with a high temporal resolution. Subsequently, spin-echo data
acquisition was restricted to the rest period duration, thereby
achieving an almost complete motion freezing of the valve and
its lesion. Overall, CMR is the most important modality in
differentiating tumor from thrombus and distinguishing benign
from malignant cardiac masses [6]. CMR can demonstrate key
indicators of malignancy including invasive behavior, tissue
inhomogeneity, and higher tissue vascularity. Nearly all malignant
tumors show post gadolinium enhancement and hyperperfusion
character [7]. Thrombus appears as a low signal intensity ﬁling
defect in the cardiac chamber. Contrast-enhanced CMR allows
differentiation between thrombus and surrounding myocardium
because thrombus is avascular and hence is characterized by an
absence of contrast uptake [8]. Late gadolinium enhancement
studies are most useful in thrombus detection as compared to the
cine studies [9]. Presence of increased signal intensity on
delayed enhancement clearly differentiates PFE from thrombus.
This will also help to delineate the thrombus if it is attached to
PFE. This case highlights the ability of CMR to characterize the
tissue characteristics, which enables non-invasive assessment for
the etiology of intra-cardiac masses. However, this case reveals
two important limitations of CMR: In the present case, tumor size
Fig. 2.
(A and B) Three-chamber and short-axis view showing a mass, attached to subvalvular posterior mitral valve apparatus (arrow) in a steady-state free precession
cine magnetic resonance image; (C and D) T1-weighted and T2-weighted turbo spin-echo sequences of the mass; (E) First-pass perfusion showing mass with no
enhancement; (F) T1-weighted inversion-recovery images after intravenous administration of gadolinium diethylene triamine pentaacetate show enhancement
of mass.
Fig. 3.
(A) Intraoperative photograph shows a mass adhering to the chordae attached to posterior mitral leaﬂet; (B) Biopsy revealed elongated and branching papillary
fronds with variable amounts of avascular collagen and elastic tissue; (C) Higher power photograph of hypocellular papillary fronds with avascular collagen core
surrounded by acid mucopolysaccharides and lined by hyperplastic endothelium.
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limitation in choosing the correct plane with the largest
dimension. We were unable to detect the presence of PFE on
aortic valve. Even with adequate CMR imaging, very small, mobile
masses can be missed on spin-echo sequences that are needed for
texture characterization.
Despite the benign nature of this tumor, it carries a
substantial risk for embolic complications, particularly strokes.
Once diagnosed, prompt surgical management is indicated even
in the asymptomatic patient [2,10]. The surgical resection is
curative, safe, and well tolerated [2,10]. Re-growth of the tumor
after resection has not been reported, but it requires long-term
TTE follow-up studies to monitor for recurrence.
Conclusions
This report highlights the rare chordal location of a PFE
without valvular involvement. A dedicated CMR protocol
for comprehensive tissue characterization is indispensable in
identifying soft tissue masses. Prompt surgical resection
with preservation of valvular integrity is recommended in most
cases.
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